Positron emission tomography (PET) in oncology: current applications and future perspectives
-
Małgorzata Trofimiuk-Müldner
and
Alicja Hubalewska-Dydejczyk
Abstract
Positron emission tomography (PET), particularly dual-modality imaging systems (PET/CT or PET/MRI), has evolved from being a research tool into a valuable clinical modality, particularly in the field of oncology. Currently, most of the PET/CT examinations are done with FDG when assessing glucose metabolism in tumors. FDG PET or PET/CT has been proven to be a valuable method in staging, restaging, therapy response assessment, early recurrence detection, and in unknown primary focus localization. However, PET/CT has its limitations, leading to both false-positive and false-negative results. Proper design and/or choice of an alternative tracer may overcome those problems as well as give better insight into tumor biology and result in more thorough assessment and effective therapeutic approach in patients with cancer.
References
1. Jones T, Price P. Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncol 2012;13:e116–25.10.1016/S1470-2045(11)70183-8Search in Google Scholar
2. Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, et al. Labeled 2-deoxy-D-glucose analogues: 18F labeled 2-deoxy-2-fluoro-D-glucose and 14C-2-deoxy-2-fluoro-D-glucose. J Labeled Comp Radiopharm 1978;14:175–83.10.1002/jlcr.2580140204Search in Google Scholar
3. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with [18F] 2-fluoro-2deoxy-D-glucose: validation of the method. Ann Neurol 1979;6:371–88.10.1002/ana.410060502Search in Google Scholar PubMed
4. Warburg O, Posener K, Negelein E. The metabolism of the cancer cells. Biochem Zietschr 1924;152:129–69.Search in Google Scholar
5. Korn LK, Coates A, Millstine J. The role of glucose and FDG metabolism in interpretation of PET studies. In: Lin EC, Alavi A, editors. PET and PET/CT. A clinical guide, 2nd ed. New York, Stuttgart: Thieme, 2008.Search in Google Scholar
6. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.10.1007/s00259-009-1297-4Search in Google Scholar PubMed PubMed Central
7. Gregoire V, Chiti A. PET in radiotherapy planning: particularly exquisite test or pending and experimental tool? Radiother Oncol 2010;96:275–6.10.1016/j.radonc.2010.07.015Search in Google Scholar PubMed
8. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumour staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357–68.10.1200/JCO.2004.08.120Search in Google Scholar PubMed
9. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480–508.10.2967/jnumed.107.047787Search in Google Scholar PubMed
10. Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MR, Rajan MG, et al. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol 2010;37: 727–40.10.1016/j.nucmedbio.2010.04.185Search in Google Scholar PubMed
11. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron tomography radiopharmaceuticals in oncology. Semin Nucl Med 2011;41:265–82.10.1053/j.semnuclmed.2011.02.002Search in Google Scholar PubMed PubMed Central
12. Haubner R. PET radiopharmaceuticals in radiation treatment planning – synthesis and biological characteristics. Radiother Oncol 2010;96:280–7.10.1016/j.radonc.2010.07.022Search in Google Scholar PubMed
13. Huang C, McConathy J. Radiolabeled Amino acids for oncologic imaging. J Nucl Med 2013;54:1007–10.10.2967/jnumed.112.113100Search in Google Scholar PubMed
14. Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374–80.10.1007/s00259-006-0206-3Search in Google Scholar PubMed
15. Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39:1977–95.10.1007/s00259-012-2215-8Search in Google Scholar PubMed PubMed Central
16. Schuster DM, Nieh PT, Jani AB, Amzat R, Bowman FD, Halkar RK, et al. Anti-3-[18F]FACBC PET-CT and 111In-capromab-pendetide SPECT-CT in recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2013 Oct 18. pii: S0022-5347(13)05682-6. doi: 10.1016/j.juro.2013.10.065. [Epub ahead of print].10.1016/j.juro.2013.10.065Search in Google Scholar PubMed PubMed Central
17. Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med 2013;54:1685–8.10.2967/jnumed.113.126094Search in Google Scholar PubMed
18. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013;64:106–17.10.1016/j.eururo.2013.04.019Search in Google Scholar PubMed
19. Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013;38:305–14.10.1097/RLU.0b013e3182867f3cSearch in Google Scholar PubMed
20. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012;15:45–55.10.1038/pcan.2011.35Search in Google Scholar PubMed
21. Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumours other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451–61.10.1007/s12149-012-0602-7Search in Google Scholar PubMed
22. Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of 18F-fluoride PET/CT in bening and malignant bone diseases. Bone 2012;50:128–39.10.1016/j.bone.2011.09.053Search in Google Scholar PubMed
23. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287–97.Search in Google Scholar
24. Ambrosini V, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S. PET/CT with 68gallium-DOTA-peptides in NET: an overview. Eur J Radiol 2011;80:e116–9.10.1016/j.ejrad.2010.07.022Search in Google Scholar PubMed
25. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80–7.10.1007/s12020-012-9631-1Search in Google Scholar PubMed
26. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004–10.10.1007/s00259-010-1512-3Search in Google Scholar PubMed
27. Wright BD, Lapi SE. Designing the magic bullet? The advancement of immuno-PET into clinical use. J Nucl Med 2013;54:1171–4.10.2967/jnumed.113.126086Search in Google Scholar PubMed
28. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 2012;30:3884–92.10.1200/JCO.2012.42.4887Search in Google Scholar PubMed PubMed Central
29. Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med 2013;54;903–12.10.2967/jnumed.112.112201Search in Google Scholar PubMed
30. Chalkidou A, Landau DB, Odell EW, Cornelius VR, O’Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 2012;48:3499–513.10.1016/j.ejca.2012.05.001Search in Google Scholar PubMed
31. Carlin S, Humm JL. PET of hypoxia: current and future perspectives. J Nucl Med 2012;53:1171–4.10.2967/jnumed.111.099770Search in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin/Boston
Articles in the same Issue
- Frontmatter
- Original Articles
- 3D PET image reconstruction based on the maximum likelihood estimation method (MLEM) algorithm
- List-mode reconstruction in 2D strip PET
- Calibration of photomultipliers gain used in the J-PET detector
- A novel method for calibration and monitoring of time synchronization of TOF-PET scanners by means of cosmic rays
- Plastic scintillators for positron emission tomography obtained by the bulk polymerization method
- J-PET analysis framework for the prototype TOF-PET detector
- Trigger-less and reconfigurable data acquisition system for positron emission tomography
- A novel method based solely on field programmable gate array (FPGA) units enabling measurement of time and charge of analog signals in positron emission tomography (PET)
- Review
- Positron emission tomography (PET) in oncology: current applications and future perspectives
Articles in the same Issue
- Frontmatter
- Original Articles
- 3D PET image reconstruction based on the maximum likelihood estimation method (MLEM) algorithm
- List-mode reconstruction in 2D strip PET
- Calibration of photomultipliers gain used in the J-PET detector
- A novel method for calibration and monitoring of time synchronization of TOF-PET scanners by means of cosmic rays
- Plastic scintillators for positron emission tomography obtained by the bulk polymerization method
- J-PET analysis framework for the prototype TOF-PET detector
- Trigger-less and reconfigurable data acquisition system for positron emission tomography
- A novel method based solely on field programmable gate array (FPGA) units enabling measurement of time and charge of analog signals in positron emission tomography (PET)
- Review
- Positron emission tomography (PET) in oncology: current applications and future perspectives
